Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (KCT0011523) titled 'Study for Epcoritamab Plus Chemotherapy as Bridging therapy in Patients with Diffuse large B-cell Lymphoma prior to CAR-T cell therapy' on Jan. 22.
Study Type: Interventional Study
Study Design:
Primary Purpose : Treatment, Intervention Model : Other(investigator's choice design in which the investigator selects either Epcoritamab+ICE or Epcoritamab+GemOx based on clinical judgment.), Blinding/Masking : Open, Allocation : Non-RCT
Primary Sponsor: Asan Medical Center
Condition:
Neoplasms
Intervention:
Drug : A single 28-day cycle of bridging therapy is administered prior to tisagenlecleucel infusion
Epcoritamab (...